ClinConnect ClinConnect Logo
Search / Trial NCT06435975

Physical Activity in Rectal Cancer Survivors

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · May 29, 2024

Trial Information

Current as of June 05, 2025

Completed

Keywords

Rectal Cancer Physical Activity Bowel Dysfunction Telehealth

ClinConnect Summary

The goal of this clinical trial is to administer and determine the feasibility of a personalized physical activity intervention for rectal cancer survivors. Structured physical activity interventions will be administered over a three-month period. An exit interview will be conducted at the completion of this time period.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Diagnosis of Stage I-III cancers of the rectum/rectosigmoid.
  • 2. Age 18 or older
  • 3. Three months to 5 years post-treatment completion
  • 4. Have a rectal or anal anastomosis with a LARS score of 21-42
  • 5. At least 10 participants must be racial/ethnic minority (Black/African American, Hispanic/Latino)
  • 6. Ability to be physically active and cleared by MD
  • 7. Patients must be able to read and understand English.
  • 8. Participants must sign the informed consent form
  • The study is open to anyone regardless of gender or ethnicity. Efforts will be made to extend the accrual to a representative population, but in a trial which will accrue 20 subjects, a balance must be struck between subject safety considerations and limitations on the number of individuals exposed to potentially toxic or ineffective treatments on the one hand and the need to explore gender, racial, and ethnic aspects of clinical research on the other. If differences in outcome that correlate to gender, racial, or ethnic identity are noted, accrual may be expanded, or additional studies may be performed to investigate those differences more fully.
  • Exclusion Criteria:
  • 1. Patients failing to meet all the above inclusion criteria will be excluded from the study.

About Abramson Cancer Center At Penn Medicine

The Abramson Cancer Center at Penn Medicine is a leading academic institution dedicated to advancing cancer research, treatment, and prevention. As part of the University of Pennsylvania, the center integrates cutting-edge scientific discovery with comprehensive clinical care, offering patients access to innovative therapies and clinical trials. Renowned for its multidisciplinary approach, the Abramson Cancer Center collaborates with experts across various specialties to deliver personalized treatment plans while fostering a supportive environment for patients and their families. Committed to improving outcomes and quality of life for cancer patients, the center is at the forefront of groundbreaking research initiatives and educational programs aimed at transforming cancer care.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Erica Pettke, MD, MPH, FACS

Principal Investigator

University of Pennsylvania

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported